TTI 621

Drug Profile

TTI 621

Alternative Names: CD47 antigen/SIRPalpha protein modulator - Trillium Therapeutics; SIRPaFc; SIRPalphaFc; TTI-621

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer Trillium Therapeutics Inc
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; SIRPA protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies; Mycosis fungoides; Small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Nov 2017 Immunogenicity data from two phase I trials in Solid tumours and Haematological malignancies released by Trillium Therapeutics
  • 07 Jun 2017 Phase-I clinical trials in Small cell lung cancer (Monotherapy, Second-line therapy or greater) in USA, Canada (IV)
  • 03 Apr 2017 Efficacy data from a phase I trial in Haematological malignancies presented at the 110th American Association for Cancer Research Annual Meeting (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top